Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability.
The authors report a retrospective analysis of the use of mycophenolate mofetil (MyM) in 85 patients with autoimmune myasthenia gravis. The Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS) was used to characterize the treatment response in each patient. Sixty-two patients (73%) achieved a PIS status indicating improvement. Quantitative strength testing performed on the majority of patients before and after treatment also improved. Side effects to MyM were observed in 27% of patients but required discontinuation in only 6%.
Meriggioli
M N
MN
Department of Neurological Sciences, Rush University, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612, USA. Matthew_N_Meriggioli@rush.edu
Ciafaloni
E
E
Al-Hayk
K A
KA
Rowin
J
J
Tucker-Lipscomb
B
B
Massey
J M
JM
Sanders
D B
DB
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000175:diagnosis / Q000188:drug therapy*; D009173:Mycophenolic Acid / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid